Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZB004 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ZB004 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ZB004 | DRUG | ZB004 single doses administered subcutaneously as solution |
| Placebo | DRUG | Placebo single doses administered subcutaneously as solution |
Inclusion Criteria: * Healthy male or female participants 18 to 55 years of age. * Body weight ≥ 50 kg for male participants and ≥ 45 kg for female participants; body mass index of 18 to 35 kg/m\^2 for both male and female participants. * Considered in good health as determined by the Investigator....
ZB004 is an investigational small molecule being developed by Zenas BioPharma, Inc. It is currently in Phase 1 clinical development. A completed Phase 1 study evaluated its safety and pharmacokinetics in healthy volunteers.
ZB004 is being studied in healthy volunteers as part of early clinical development. The completed Phase 1 trial assessed its safety and pharmacokinetics in this population. Its intended therapeutic use has not been established.
ZB004 is being developed by Zenas BioPharma, Inc., a biopharmaceutical company. The company's stock trades under the ticker ZBIO.
ZB004 is in Phase 1 clinical development. A Phase 1 study of ZB004 in healthy participants has been completed. The drug remains investigational and has not been approved by regulatory authorities.
ZB004 has one completed clinical trial, NCT05794516, titled "A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants." This Phase 1 study enrolled 40 healthy volunteers in New Zealand and was placebo-controlled, randomized, and double-blind.
ZB004 is a distinct investigational small molecule developed by Zenas BioPharma, Inc. No alternative names for ZB004 have been reported in its clinical trial record.